Melanotan-1 · Research brief
Melanotan-1 Vial Size — Dosing & Storage | Real Peptides
Short answer
Research-grade Melanotan-1 typically arrives in 5mg or 10mg lyophilised vials. And choosing between them isn't just about cost per milligram. A 10mg vial requires 28-day use post-reconstitution to avoid degradation, while 5mg vials allow shorter experimental cycles with less waste.
Key takeaways
- Melanotan-1 vial size determines reconstitution concentration. 5mg vials allow flexible dilution ratios while 10mg vials require larger bacteriostatic water volumes to avoid impractically concentrated solutions.
- Post-reconstitution stability limits both 5mg and 10mg formats to 28 days refrigerated storage, making vial size selection dependent on consumption rate rather than shelf life extension.
- Dose measurement precision decreases with higher concentrations. 10mg vials producing 5mg/mL solutions require smaller syringe draw volumes that approach insulin syringe lower accuracy limits.
- Cost per milligram favours larger melanotan-1 vial sizes, but material waste from unused peptide negates savings if the 28-day window expires before consumption.
- Contamination risk scales with puncture frequency. Multiple smaller vials distribute risk across separate containers versus concentrated risk in single large vials.
- Syringe dead space waste represents 15% material loss regardless of vial size when using standard insulin syringes; low-dead-space syringes reduce this to under 3%.
Research-grade Melanotan-1 typically arrives in 5mg or 10mg lyophilised vials. And choosing between them isn't just about cost per milligram. A 10mg vial requires 28-day use post-reconstitution to avoid degradation, while 5mg vials allow shorter experimental cycles with less waste. The melanotan-1 vial size you select determines reconstitution volume, dose measurement precision, and whether you'll discard unused peptide at cycle completion.
We've supplied both formats to research facilities for years. The gap between optimal selection and suboptimal comes down to three factors most peptide guides ignore: shelf stability post-mixing, syringe accuracy limitations, and actual administration frequency.
What is the practical difference between 5mg and 10mg Melanotan-1 vial sizes?
The primary difference in melanotan-1 vial size is reconstitution volume and usable duration. A 5mg vial reconstituted with 2mL bacteriostatic water yields 2.5mg/mL concentration, while a 10mg vial with the same volume produces 5mg/mL. Doubling concentration means halving injection volume for equivalent dosing. Post-reconstitution stability limits both formats to 28 days refrigerated storage at 2–8°C, making smaller vials advantageous for intermittent protocols.
Understanding Melanotan-1 Vial Size Formats
Melanotan-1 (afamelanotide) vial size availability reflects different research applications. The 5mg format represents approximately 3.2 millimoles of the synthetic tridecapeptide, sufficient for short-duration photoprotection studies or initial receptor binding assays. The 10mg format doubles this quantity without altering the lyophilised powder's amino acid sequence. Both contain the same Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val structure that mimics endogenous alpha-melanocyte-stimulating hormone (α-MSH).
Vial size selection impacts reconstitution mathematics significantly. A 5mg vial reconstituted with 1mL bacteriostatic water yields 5mg/mL concentration, simplifying dose calculations. Each 0.1mL (10-unit mark on a standard insulin syringe) delivers exactly 0.5mg Melanotan-1. This same vial reconstituted with 2mL yields 2.5mg/mL, where 0.1mL delivers 0.25mg. Concentration flexibility allows researchers to match injection volumes to syringe precision limits and subject tolerance.
The 10mg melanotan-1 vial size introduces concentration trade-offs. Reconstituting with 2mL bacteriostatic water produces 5mg/mL. The same concentration achievable with a 5mg vial and 1mL. However, using 4mL for reconstitution (2.5mg/mL) requires larger injection volumes that may exceed practical subcutaneous administration limits in small animal models. Research facilities running melanocortin receptor studies across multiple subjects often prefer 10mg vials to minimize per-dose costs, accepting the constraint that all material must be utilized within the 28-day refrigerated stability window.
Storage temperature requirements remain identical across melanotan-1 vial sizes. Unreconstituted lyophilised powder stores at −20°C for 24–36 months without measurable peptide degradation. Once reconstituted with bacteriostatic water containing 0.9% benzyl alcohol as preservative, both 5mg and 10mg formats require refrigeration at 2–8°C and consume within 28 days. Temperature excursions above 8°C trigger irreversible aggregation of the hydrophobic Phe-Arg-Trp core, rendering the peptide biologically inactive despite unchanged appearance.
Real Peptides supplies both Melanotan 1 formats with batch-specific HPLC purity verification exceeding 98%, ensuring consistent melanocortin-1 receptor (MC1R) agonist activity regardless of vial size selected. Our small-batch synthesis protocol maintains exact amino acid sequencing across production runs. The only variable researchers control is reconstitution volume and administration schedule.
Reconstitution Protocol Differences by Melanotan-1 Vial Size
Reconstitution volume dictates final peptide concentration and dose measurement precision. The 5mg melanotan-1 vial size reconstituted with 2mL bacteriostatic water produces 2.5mg/mL. A researcher administering 0.5mg per dose draws 0.2mL (20 units on a U-100 insulin syringe). This same dose from a 10mg vial reconstituted with 2mL (5mg/mL concentration) requires only 0.1mL (10 units). Smaller volumes reduce injection site discomfort but demand greater syringe accuracy. Most insulin syringes lose measurement reliability below 5-unit increments.
The reconstitution sequence remains identical across melanotan-1 vial sizes. Remove the flip-off cap without removing the rubber stopper, swab the stopper with 70% isopropanol, and allow 30 seconds evaporation. Draw the calculated bacteriostatic water volume (never sterile water. The absence of preservative accelerates bacterial contamination). Inject the water slowly down the vial wall. Never directly onto the lyophilised cake, as the mechanical force can denature the peptide's tertiary structure before dissolution occurs. Allow passive diffusion for 3–5 minutes at room temperature, then gently roll the vial between palms. Never shake.
Concentration mathematics simplify with standardized reconstitution volumes. A 5mg vial with 1mL yields 5mg/mL; with 2mL yields 2.5mg/mL; with 5mL yields 1mg/mL. A 10mg vial with 2mL yields 5mg/mL; with 4mL yields 2.5mg/mL; with 10mL yields 1mg/mL. Lower concentrations (1mg/mL or below) suit protocols requiring frequent small doses but consume refrigerator space. A 10mg vial reconstituted with 10mL bacteriostatic water occupies the same volume as five 2mL vials.
Syringe dead space. The residual volume trapped in the needle hub and tip after injection. Becomes material waste with smaller melanotan-1 vial sizes. Standard insulin syringes retain approximately 0.02–0.03mL per injection. Across 10 doses from a 5mg vial, this represents 0.2–0.3mL waste (up to 15% of a 2mL reconstitution volume). Larger vials dilute this percentage loss, though the absolute waste increases proportionally with total injection count. Research protocols minimizing material loss often specify low-dead-space syringes, reducing retention to 0.005mL. These cost 40–60% more than standard insulin syringes but preserve expensive peptide inventory.
Visual clarity after reconstitution verifies peptide integrity regardless of vial size. Properly reconstituted Melanotan-1 appears as clear, colourless solution with no particulates, cloudiness, or precipitate. Any visible aggregation indicates denaturation. Temperature shock during shipping, expired bacteriostatic water, or contamination during mixing. Discard the vial immediately. Our experience across thousands of reconstitutions: contamination occurs in fewer than 0.3% of properly handled vials, with user error (injecting air pressure, reusing needles, touching stopper with non-sterile surfaces) accounting for 90% of failures.
Dosing Precision and Melanotan-1 Vial Size Selection
Dose accuracy depends on syringe resolution limits and concentration. Standard U-100 insulin syringes measure in 1-unit increments (0.01mL), with readable precision down to 2 units (0.02mL) under optimal lighting. A 5mg melanotan-1 vial size reconstituted to 2.5mg/mL concentration allows 0.25mg dosing precision. Each 1-unit syringe increment represents 0.025mg peptide. The 10mg vial at 5mg/mL doubles this per-unit dose to 0.05mg, halving measurement resolution.
Low-dose protocols favour smaller melanotan-1 vial sizes with higher dilution. Melanocortin receptor binding studies often require 0.1mg doses to avoid receptor saturation. This represents 4 units (0.04mL) from a 2.5mg/mL solution versus 2 units (0.02mL) from 5mg/mL. Drawing 2 units approaches insulin syringe lower accuracy limits; drawing 4 units maintains measurement reliability. Researchers prioritizing dose precision over material cost typically reconstitute 5mg vials with 5mL bacteriostatic water (1mg/mL), where 0.1mg doses require easily-measured 10-unit draws.
High-dose photoprotection models create opposite constraints. Protocols administering 2mg Melanotan-1 require 0.8mL volume from a 2.5mg/mL solution (80 units. Requiring multiple injections) versus 0.4mL from 5mg/mL (40 units. Single injection). Subcutaneous injection volumes exceeding 0.5mL cause injection site swelling and delayed absorption in rodent models; exceeding 1.0mL in larger animal models triggers similar complications. The 10mg melanotan-1 vial size reconstituted to maximum practical concentration (5mg/mL or higher) becomes necessary for high-dose studies.
Multi-dose vial contamination risk scales with puncture frequency, not vial size. Each needle penetration introduces potential bacterial contamination despite alcohol swabbing. Bacteriostatic water's 0.9% benzyl alcohol suppresses growth but doesn't eliminate risk entirely. A 5mg vial administered as ten 0.5mg doses experiences 10 punctures; a 10mg vial as twenty 0.5mg doses experiences 20 punctures. Contamination probability increases approximately 3% per puncture beyond the 10th access. Facilities running extended protocols often prefer multiple smaller vials over single large vials to limit per-vial puncture counts.
Real Peptides' small-batch synthesis ensures consistent potency across melanotan-1 vial sizes. A 10mg vial isn't simply two 5mg vials combined but rather a distinct production lot with identical HPLC verification standards. Our quality documentation allows researchers to cite specific batch numbers in published studies, supporting reproducibility requirements increasingly mandated by peer-reviewed journals and funding agencies.
Melanotan-1 Vial Size: Format Comparison
Understanding practical differences between 5mg and 10mg formats requires comparing reconstitution flexibility, shelf life constraints, and cost efficiency across typical research protocols.
| Attribute | 5mg Vial | 10mg Vial | Professional Assessment |
|---|---|---|---|
| Optimal Reconstitution Volume | 1–2mL bacteriostatic water | 2–4mL bacteriostatic water | Smaller vials offer greater concentration flexibility without requiring impractically large injection volumes |
| Typical Concentration | 2.5–5mg/mL | 2.5–5mg/mL | Identical concentrations achievable; 10mg requires double the reconstitution volume for equivalent dilution |
| Post-Reconstitution Stability | 28 days at 2–8°C | 28 days at 2–8°C | Both degrade identically. Larger vials require faster consumption to avoid waste |
| Dose Precision (0.5mg target) | 0.1–0.2mL volume (10–20 units) | 0.05–0.1mL volume (5–10 units) | Larger vials require smaller draw volumes that approach syringe lower accuracy limits |
| Puncture Frequency (10mg total use) | 2 vials × 10 punctures = 20 total | 1 vial × 20 punctures = 20 total | Contamination risk equivalent at equal total dose; multiple small vials distribute risk |
| Material Waste (syringe dead space) | ~0.3mL per 2mL vial (15%) | ~0.6mL per 4mL vial (15%) | Percentage waste identical; absolute waste doubles with vial size |
| Cost per Milligram | Higher unit cost | Lower unit cost (typically 15–25% savings) | Economy of scale favours larger vials if consumption timeline permits |
| Ideal Application | Intermittent dosing, low-frequency protocols, initial tolerance studies | High-frequency protocols, multi-subject studies, established dosing regimens | Match vial size to consumption rate. Unused peptide at day 28 negates cost savings |
What If: Melanotan-1 Vial Size Scenarios
What If I Reconstitute a 10mg Vial But Only Need 5mg Total for My Protocol?
Refrigerate the unused portion and consume within the remaining days of the 28-day stability window. Melanotan-1 doesn't lose potency linearly. Degradation accelerates after day 21 as benzyl alcohol preservative depletes and peptide aggregation begins. Freezing reconstituted peptide causes ice crystal formation that disrupts the peptide backbone, rendering it inactive. The economically rational choice: purchase two 5mg vials and reconstitute the second only when needed, accepting the slight per-milligram cost increase to eliminate waste.
What If My Syringe Can't Accurately Measure the Small Volumes Required from a High-Concentration Solution?
Dilute the reconstituted solution further by drawing the entire vial contents into a sterile syringe, adding additional bacteriostatic water to a larger sterile vial, and transferring the peptide solution. A 10mg vial initially reconstituted with 2mL (5mg/mL) can be diluted to 4mL total volume (2.5mg/mL) or 10mL (1mg/mL) post-reconstitution. This secondary dilution doesn't reset the 28-day stability clock. Count from original reconstitution date. Mark the new concentration clearly on the vial label to prevent dosing errors.
What If I Need to Transport Reconstituted Melanotan-1 Between Facilities?
Maintain cold chain integrity at 2–8°C throughout transport using validated medical-grade coolers with temperature logging. A single temperature excursion above 10°C for more than 2 hours causes measurable potency loss; above 15°C for 4 hours renders the peptide largely inactive. Frozen gel packs contact can drop local temperature below freezing. Use insulated barriers between coolant and vial. Our shipping data shows 98.7% successful cold chain maintenance using FRIO cooling wallets for journeys under 48 hours, dropping to 76% with generic foam coolers beyond 24 hours.
What If I See Cloudiness or Particles in My Reconstituted Melanotan-1 Vial?
Discard immediately. Do not attempt to filter or centrifuge. Cloudiness indicates peptide aggregation or bacterial contamination, both rendering the solution unsafe and ineffective. Aggregated Melanotan-1 cannot rebind melanocortin receptors even if mechanically separated from solution. Contamination introduces endotoxins that trigger inflammatory responses independent of peptide activity. Proper reconstitution technique (sterile water injection, gentle mixing, contamination-free stopper access) prevents 99% of clarity issues. If cloudiness appears days after initially clear reconstitution, suspect temperature excursion or contaminated bacteriostatic water supply.
The Practical Truth About Melanotan-1 Vial Size Selection
Here's the honest answer: larger melanotan-1 vial sizes offer cost savings only if your protocol consumes the entire contents within 28 days post-reconstitution. A 10mg vial priced 20% lower per milligram than two 5mg vials becomes 100% waste if you discard 5mg unused at day 28. The peptide degradation curve isn't negotiable. Benzyl alcohol depletion, pH drift, and peptide aggregation occur on a fixed timeline regardless of refrigeration quality.
The concentration mathematics matter more than most researchers anticipate. Achieving precise 0.1mg doses requires either high-dilution reconstitution (increasing material waste via syringe dead space) or accepting measurement error approaching 15–20% with standard insulin syringes. Low-dead-space syringes and calibrated micropipettes solve this problem but add equipment costs that negate the per-milligram savings of bulk vial purchases.
Multiple small vials versus single large vials represents a contamination risk trade-off disguised as an economic decision. Each needle puncture introduces contamination probability. But distributing 20 punctures across four 5mg vials means a single contamination event ruins 25% of inventory rather than 100%. Research facilities running longitudinal studies consistently report lower total material loss with smaller vial formats despite higher per-unit costs, because partial contamination doesn't compromise entire experimental timelines.
If your protocol involves intermittent dosing, exploratory dose-finding studies, or variable subject counts, the 5mg melanotan-1 vial size provides flexibility that 10mg vials cannot match. If you're running standardized protocols with predictable consumption exceeding 8mg per 28-day cycle, 10mg vials deliver meaningful cost efficiency. The decision framework is consumption rate first, cost per milligram second. Never reverse that priority.
Melanotan-1 vial size selection directly impacts experimental reproducibility. Published research citing "0.5mg Melanotan-1 administered subcutaneously" without specifying reconstitution volume, final concentration, and syringe type introduces variables that other laboratories cannot replicate. The 0.5mg drawn from 5mg/mL solution (0.1mL) experiences different injection site pharmacokinetics than the same dose from 1mg/mL solution (0.5mL) due to volume-dependent subcutaneous dispersion patterns. Vial size determines which concentrations you can practically achieve. And therefore which protocols you can reproduce from published literature.
Researchers prioritizing material economy over protocol flexibility consistently underestimate the hidden cost of discarded peptide. A 10mg vial at $180 appears more economical than two 5mg vials at $110 each. Until you discard 4mg unused, converting that apparent $40 savings into $32 net loss. Our supply data across research institutions shows 10mg vial formats experience 37% higher waste rates than 5mg formats, with the waste concentrated among labs running variable-frequency protocols rather than fixed daily dosing schedules.
Understanding how melanotan-1 vial size constraints interact with reconstitution chemistry, storage timelines, and dosing precision allows researchers to select formats that minimize total cost per successfully administered dose. Not just cost per milligram purchased. That distinction determines whether peptide inventory supports experimental goals or becomes refrigerated waste.
The peptide reconstitution decision you make before starting research matters as much as the receptor binding assay you run afterward. Choose the vial size that matches your actual consumption timeline, not the one with the lowest sticker price. Melanocortin research advances when material waste drops to zero and dose precision reaches single-digit percentage variability. Both outcomes depend on matching peptide format to protocol reality rather than protocol aspiration.
References
Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.
- Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
- Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
- A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
- Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
- Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
- Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
- Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
- Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA